iShares Genomics Immunology and Healthcare ETF

IDNA

Market cap $192M

IDNA Hedge Fund Activity: Q1 2026 in Review

60 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q1 2026, worth a combined $61.8M — up 12% from $55M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IDNA positions and 6 closed out — a net gain of 3 holders — while 19 added to existing stakes and 13 trimmed.

The largest buyer was Bank of America, adding an estimated $3.25M. The largest seller was Raymond James Financial, cutting an estimated $1.85M.

• 60 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q1 2026, up from 58 in Q4 2025.
• Funds reported $61.8M of iShares Genomics Immunology and Healthcare ETF stock for Q1 2026, up 12% quarter-over-quarter.
• 9 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q1 2026 and 6 closed out, a net change of +3 holders.
• The largest iShares Genomics Immunology and Healthcare ETF buyer in Q1 2026 was Bank of America, an estimated $3.25M added.
• The largest iShares Genomics Immunology and Healthcare ETF seller in Q1 2026 was Raymond James Financial, an estimated $1.85M sold.

Based on aggregated 13F filings for Q1 2026.